Please login to the form below
Cymbalta
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Cymbalta was produced by Lilly and Shionogi.
Daily Brief: another departure at Gilead, veteran researcher to head up Karuna
Steven Paul, a veteran researcher who played a key role in developing Lilly’s antipsychotic and depression blockbuster drugs such as Zyprexa and Cymbalta is to head up efforts to find
Lilly mulls divestment of its animal health operations
Alimta (pemetrexed) and antidepressant Cymbalta (duloxetine) resulting from generic competition.
Daiichi drug hits mark in shingles pain, but misses in other indications
At the moment, there are just three approved drugs for fibromyalgia - Lyrica, Eli Lilly's Cymbalta (duloxetine) and Allergan's Savella (milnacipran) - and while these have been shown to reduce pain
Lilly’s president and chief executive John Lechleiter to retire
raloxifene) and antidepressant Cymbalta (duloxetine) have also expired.
UK court backs Actavis in dispute over Lilly's Alimta
Maintaining Alimta's revenue stream is a priority for Lilly as it weathers the loss of patent protection for other brands, including osteoporosis drug Evista (raloxifene) and antidepressant Cymbalta (duloxetine) and
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- Moderna inks R&D agreements with Vertex and Chiesi
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
bmore group
OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
